Compare FRSX & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSX | GLMD |
|---|---|---|
| Founded | N/A | 2000 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.2M |
| IPO Year | 2016 | 2013 |
| Metric | FRSX | GLMD |
|---|---|---|
| Price | $1.42 | $0.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 121.8K | 86.4K |
| Earning Date | 05-15-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.41 |
| 52 Week High | $3.00 | $2.09 |
| Indicator | FRSX | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 42.99 |
| Support Level | $1.28 | $0.41 |
| Resistance Level | $1.46 | $0.70 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 14.27 | 19.34 |
Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.